Hong Kong-Listed ETFs

ChinaAMC Hang Seng Biotech ETF (3069 HK / 9069 HK / 83069 HK)

Management fee

0.50%(p.a.)

4557

Listing Date

18-Mar-2021

Morningstar

/5

Fund Performance

-12.93%

YTD

-19.19%

1 Year

-52.63%

3 Year

-

5 Year

-62.49%

Since Inception

As of 29-11-2024

Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Biotech ETF (the “Fund”), investor should refer to the Fund’s prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

• The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Biotech Index (the “Index”).
• The Fund is passively managed. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
• The Fund’s investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
• The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
• The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and mainland China). The Fund may be more volatile than a broadly-based fund.
• The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
• The Fund is subject to securities lending transactions risks, including the risk that the borrower may fail to return the securities in a timely manner.
• The Fund is subject to tracking error risk.
• If any suspension of the inter-counter transfer of units and/or any limitation on the level of services by brokers and CCASS participants occurs, unitholders will only be able to trade their units in one counter. The market price of units traded in each counter may deviate significantly.
• Unitholders will receive distributions in the HKD only. Non HKD based unitholder may have to bear bank or financial institution fees and charges associated with currency conversion.
• The Fund’s base currency is HKD but has units traded in USD. Investors may be subject to additional costs or losses associated with foreign currency fluctuations.
• Generally, retail investors can only buy or sell units of the Fund on the SEHK. The trading price of the units on the SEHK is driven by market factors such as the demand and supply of the units. Therefore, the units may trade at a substantial premium or discount to the Fund’s NAV.

Product Details

Investment Objective

The investment objective of the Sub-Fund is to provide investment results that, before fees and expenses, closely correspond to the performance of the Hang Seng Biotech Index.

Product Overview

Underlying Asset Class Equity
Listing Date 18-03-2021
Base Currency HKD
Net Asset Value (mil) 770.24
Domicile Hong Kong
Management Fee 0.5%(p.a.)
Trustee and Registrar HSBC Institutional Trust Services (Asia) Limited
Distribution Policy Annually (usually in December), subject to the Manager’s discretion. All Units will receive distributions in HKD only.

As of 30-10-2024

Intra-day Estimated NAV and Market Price ( 2,3 )

Latest Market Information ( 4,5 )

Date Last Change Change(%)
Official NAV per Unit in HKD10-12-20249.2210-0.2338-2.47%
NAV per Unit in USD (for reference only)10-12-202471.6790-1.8902-2.57%
NAV per Unit in RMB (for reference only)10-12-20249.8953-0.1939-1.92%
Closing Price for HKD Traded Unit11-12-20249.1700-0.0300-0.33%
Closing Price for USD Traded Unit11-12-20241.1860-0.0020-0.17%
Closing Price for RMB Traded Unit11-12-20248.6300--

Trading Information

HKD Traded UnitsUSD Traded UnitsRMB Traded Units
Exchange ListingSEHK – Main BoardSEHK – Main BoardSEHK – Main Board
Commencement of Dealing18-Mar-202130-Jun-202119-Jan-2024
Stock Code3069906983069
Trading Board Lot Size100 Units100 Units100 Units
Trading CurrencyHKDUSDRMB
SEDOL CodeBMXC534BM9CF49BRF6W50
Reuters Code3069.HK9069.HK83069.HK
ISIN CodeHK0000711199HK0000744208HK0000955887
Bloomberg Ticker3069 HK9069 HK83069 HK
Bloomberg NAV3069NAV9069NAV83069NAV
Bloomberg iNAV3069IV9069IV83069IV
Bloomberg Shares Oustanding3069SHO9069SHO83069SHO

Index Information ( 6 )

IndexHang Seng Biotech Index
Index ProviderHang Seng Indexes Company Limited
CurrencyHKD
Closing Level10284.9
Change-263.08
Change (%)-2.49%
Type of IndexNet Total Return

As of 10-12-2024

Participating Dealers

  • ABN AMRO Clearing Hong Kong Limited
  • Barclays Bank PLC
  • BNP Paribas
  • China International Capital Corporation Hong Kong Securities Limited
  • China Merchants Securities (HK) Co., Limited
  • Citigroup Global Markets Asia Limited
  • Credit Suisse Securities (Hong Kong) Limited
  • DBS Vickers (Hong Kong) Limited
  • Goldman Sachs (Asia) Securities Limited
  • Guotai Junan Securities (Hong Kong) Limited
  • Haitong International Securities Company Limited
  • Huatai Financial Holdings (Hong Kong) Limited
  • J.P. Morgan Broking (Hong Kong) Limited
  • Korea Investment & Securities Asia Limited
  • Merrill Lynch Far East Limited
  • Mirae Asset Securities (HK) Limited
  • The Hongkong and Shanghai Banking Corporation Limited
  • Yue Xiu Securities Company Limited
  • Zhongtai International Securities Limited

Market Makers

HKD CounterUSD CounterRMB Counter
Flow Traders Hong Kong LimitedFlow Traders Hong Kong LimitedFlow Traders Hong Kong Limited
Optiver Trading Hong Kong LimitedOptiver Trading Hong Kong Limited

Please refer to the Hong Kong Exchanges and Clearing Limited’s website at www.hkex.com.hk for the latest lists of Market Makers.

1    Data are provided by ICE Data Indices, LLC (“ICE DATA”), is used with permission. ICE DATA, its Affiliates and their respective third party suppliers (including but not limited to Factset Research System, Inc.) disclaim any and all warranties and representations, express and/or implied, including any warranties of merchantability or fitness for a particular purpose or use, including the index data and any data included in, related to, or derived therefrom. Neither ICE DATA, its Affiliates nor their respective third party suppliers shall be subject to any damages or liability with respect to the adequacy, accuracy, timeliness or completeness of the Index data or any component thereof, and the index data and all components therefore are provided on an “as is” basis and your use is at your own risk. ICE DATA, its Affiliates and their respective third party suppliers do not sponsor, endorse, or recommend China Asset Management (Hong Kong) Limited, or any of its products or services.

2    Intra-day Estimated NAV per Unit calculations are performed by ICE DATA.

3    Intra-day Market Price refers to the market price of ChinaAMC Hang Seng Hong Kong Biotech Index on the date and at the time specified above, quoted from the Stock Exchange of Hong Kong Limited (the“SEHK”).

4    Change of the Official NAV per Unit in HKD indicate the change of the NAV per Unit since previous Dealing Day^. Please refer to the Prospectus for more information on the determination of the NAV.

5    TChanges of the Closing Price for HKD traded Units indicate the change of the closing price since previous SEHK trading day. Source of Closing Price: Bloomberg.

6   Benchmark Index returns are for illustrative purposes only and are not indicative of future results. Benchmark Index returns do not reflect any management fees, transaction costs or expenses. Change indicates the change since the last closing index level. Source: HSI, Bloomberg (see Terms and Conditions). With effect from 5 June 2023, the portfolio of the Fund was rebalanced to reflect the changes to the Index methodology. The performance of the Fund prior to 5 June 2023 was achieved under circumstances that no longer apply.

^ “Dealing Day” generally means a day on which (a) the SEHK is open; and (b) the Index is compiled and published. Please refer to the Prospectus for further details in this regard.

Returns/Historical NAVs Chart

Fund Price

Class Currency Dealing Date NAV per unit
HKD HKD 10-12-2024 9.2210
USD USD 10-12-2024 71.6790
RMB RMB 10-12-2024 9.8953

Since Launch Performance

Returns
Historical NAVs
HKD
HKD

ETF listing date: 18 March 2021

With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply.

Investment involves risks. Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested. These figures show by how much the Fund increased or decreased in value during the calendar year being shown. Performance data has been calculated in the base currency of the share class (or the ETF), including ongoing charges and excluding subscription and redemption fees and trading costs on SEHK (if applicable). Where no past performance is shown there was insufficient data available in that year to provide performance. Please refer to the Fund Overview section for the inception date of the share class (or the listing date of the ETF).

7 Day Annualized

Holdings

Top 10 Holdings

Holdings. Weighting (%)
WUXI BIOLOGICS CAYMAN INC 10.3
BEIGENE LTD 9.33
INNOVENT BIOLOGICS INC 8.46
AKESO INC 6.28
CHINA PHARMACEUTICAL GROUP 6.28
SINO BIOPHARMACEUTICAL 5.2
GIANT BIOGENE HOLDING CO LTD 3.55
HANSOH PHARMACEUTICAL GROUP 3.31
ZAI LAB LTD 3.29
WUXI APPTEC CO LTD-H 3.04
Total 59.04

As of 10-12-2024

Holding Details

Click below button to show the details of the holdings

Holdings are subject to change. Total allocation percentages shown in the Holdings table may not equal 100% due to rounding,  The historical data provided herein is for reference only and does not represent any future performance.

Sector Breakdown

As of 10-12-2024

Country Breakdown

As of 10-12-2024

Yield Information

There is currently no information available.

Asset Allocation

Asset Typs Weighting(%)
Health Care 89.22%
Consumer Discretionary 4.4%
Consumer Staples 3.56%
#N/A 2.42%

As of 10-12-2024

Tracking Difference & Error

Tracking Difference (TD):

Tracking difference is the return difference between the ETF and its underlying benchmark/ index over a certain period of time.

Tracking Error (TE):

Tracking error measures how consistently the ETF follows its benchmark/ index. It is the volatility (measured by standard deviation) of that return difference.

Tracking Difference / Tracking Error

Rolling 1-Year TD-0.24%
Rolling 1-Year TE^0.91%
TD (2022)-0.44%
TD (2023)-0.59%

As of 30-11-2024

^Annualized based on the number of dealing days in the last year when daily TD is calculated

Graph for Tracking Difference

Calendar Year Performance (#)​

The FundIndex(Price Return)Index(Total Return)
2023-23.59%-23.98%-23.15%
2022-18.31%-18.7%-17.72%

As of 31-12-2023

#The benchmark of the ETF is Hang Seng Hong Kong-Listed Biotech Index

 

Past performance Vs Benchmark performance

ETF listing date: 18 March 2021

With effect from 8 November 2021, the investment strategy of the Fund was changed. The performance of the Fund prior to 8 November 2021 was achieved under circumstances that no longer apply.

Investment involves risks. Past performance information is not indicative of future performance. Investors may not get back the full amount invested. The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividend reinvested. These figures show by how much the Fund increased or decreased in value during the calendar year being shown. Performance data has been calculated in the base currency of the share class (or the ETF), including ongoing charges and excluding subscription and redemption fees and trading costs on SEHK (if applicable). Where no past performance is shown there was insufficient data available in that year to provide performance. Please refer to the Fund Overview section for the inception date of the share class (or the listing date of the ETF).

Distribution History

Ex-Dividend Date Record Date Pay Date Currency Total Distribution Per Unit Dividend paid out of net distributable income * (HKD) Dividend paid out of capital
18-12-2024 19-12-2024 31-12-2024 HKD 0.06 100% 0%
18-12-2023 19-12-2023 29-12-2023 HKD 0.03 100% 0%
19-12-2022 20-12-2022 30-12-2022 HKD 0.04 100% 0%

Prospectus & Documents

Factsheet
Financial Reports
Fund Brochure
Offering Documents
File name Date File Format
Brochure 17-03-2021 PDF >
File name Date File Format
Prospectus 09-12-2024 PDF >
Product Key Facts 09-12-2024 PDF >

Announcements & Notices

Investing involves risk, including possible loss of principal. Investment in emerging market countries may involve heightened risks such as increased volatility and lower trading volume, and may be subject to a greater risk of loss than investment in a developed country. Please carefully consider the Fund’s investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the relevant Fund’s prospectus. Please read the prospectus carefully before investing. ChinaAMC Funds are not sponsored, endorsed, issued, sold or promoted by their index providers (only applicable to ETFs and index funds). For details of an index provider including any disclaimer, please refer to the relevant ChinaAMC Fund offering documents.

Source: Fund performance and index data are provided by ChinaAMC and the relevant index providers (if applicable) respectively.

This website is prepared by China Asset Management (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission.

FAQs

FAQs

Remarks
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

Performance Simulator

Performance Simulator

Please select the simulation period

Start date:

End date:

Simulation Results

The Product

0%

Index

0%

Leverage/Inverse

0%

Performance Chart

Remarks
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.

Important Notes:

Add Your Heading Text Here

Important Notes:

Private Funds

ChinaAMC(HK) is uniquely positioned in the market which enables it to leverage its extensive knowledge, research capabilities and investment experience in China to deliver a range of high-value asset management or investment advisory services to institutional clients worldwide. To bridge overseas investors with China opportunities, ChinaAMC (HK) is committed to utilize its local expertise to capture enormous investment potentials in China.

The private fund products issued and managed by ChinaAMC (HK) include Cayman Islands registered funds and Luxembourg domiciled SICAV funds*.

Browse through our website and discover our investment strategies. For private fund products information, please visit the product page by logging into your account.

* SICAV fund is an open-ended collective investment scheme common in Western Europe and may be open to public investors in certain European countries depending on its registration status.

Welcome back

Lorem ipsum dolor sit amet, conse ctetuer adipi scing elitenean.